CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Up 10% – Time to Buy?

CytoMed Therapeutics Limited (NASDAQ:GDTC) shares rose 10% during trading on Wednesday . The company traded as high as $0.99 and last traded at $0.99. Approximately 3,378 shares changed hands during trading, a decline of 99% from the average daily volume of 439,687 shares. The stock had previously closed at $0.90.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CytoMed Therapeutics in a research report on Friday, April 10th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

CytoMed Therapeutics Price Performance

The firm has a 50-day moving average price of $1.03 and a 200-day moving average price of $1.39. The company has a debt-to-equity ratio of 0.06, a current ratio of 5.17 and a quick ratio of 5.17.

CytoMed Therapeutics (NASDAQ:GDTC) last announced its earnings results on Sunday, February 15th. The company reported ($0.06) earnings per share (EPS) for the quarter. The firm had revenue of $0.06 million during the quarter.

CytoMed Therapeutics Company Profile

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury.